Column

We would like to introduce the data for a serological marker from our MASH model (STAM^TM model).

Hepatocellular ballooning is a key finding distinguishing MASH from simple steatosis in terms of MASH diagnosis. CK-18 (cytokeratin 18) is known as one of the promising non-invasive biomarkers and was also recommended at the AASLD-FDA joint workshop because it is useful for diagnosing an early phase MASH.

Below is the results of plasma CK-18 levels in the STAM^TM model.

– Elevates from 6 weeks of age, representing early MASH

– Gradually increases with progression of disease (from simple fatty liver to MASH, fibrosis)

– Shows similar rise to human MASH patients [Ariel E. Feldstein et al., Hepatology, 2009]

Our STAM^TM model is the world’s first MASH to HCC mouse model developed by SMC Laboratories, which has a background of late-stage type 2 diabetes and develops a pathology similar to human MASH (fatty liver →MASH → liver fibrosis → HCC).
 
For more information on the STAM^TM mouse model, please click below page.